FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386660211> ?p ?o ?g. }

• W4386660211 abstract "Abstract Background Direct oral anticoagulants (DOACs) have demonstrated to the be more effective and safer than vitamin-K antagonist (VKA) for stroke prevention in patients with atrial fibrillation (AF). AF prevalence increases exponentially with age but octogenarians were underrepresented in clinical trials. Methods We performed a metanalysis with currently available studies that assessed the effect of DOACS vs. VKA in patients with age ≥80 and AF after performing a systematic search. The primary endpoints analyzed were stroke and all-cause death. Secondary endpoints were major bleeding, according to each study definitions, intracranial bleeding and gastrointestinal (GI) bleeding. The raw numbers of incident end-points reported in each study were used. A random effects model was selected because significant heterogeneity was observed; sensitivity analyses tested potential sources of heterogeneity, publication bias and the small-study effect. Results A total of 147,067 patients from 16 studies were included, 71,913 treated with DOACs and 75,154 with VKA. Inclusion criteria for the study was age ≥80 in 13 studies, ≥85 in two and ≥90 in one. Mean age of patients included all the studies was 86.2 (2.6) years. According to the study drug, 34,448 received rivaroxaban; 20,295 apixaban; 14,641 dabigatran, 492 edoxaban and; 2,037 any DOAC. No difference in mean age was observed according to the study drug. Stroke incidence was available in the 16 studies. DOACs treatment was associated to 28% reduction of stroke (RR: 0.72 95% CI 0.63–0.82; p&lt;0.001) (figure). All-cause mortality could be assessed in 12 studies and DOACs treatment was associated to 18% in mortality (RR: 0.82, 95% CI 0.70–0.96; p=0.012) (figure). DOACs treatment was not associated to reductions in major bleeding (RR: 0.85, 95% CI 0.69–1.04; p=0.108); in contrast, the highest effect of DOACs treatment was a 43% reduction of intracranial bleeding (RR: 0.47, 95% CI 0.36–0.60; p&lt;0.001) (Figure 4). Finally, DOACs treatment was not associated higher of GI bleeding risk (RR: 1.08, 95% CI 0.76–1.53; p=0.678). Metaregression identified inclusion site in North-America (p&lt;0.001), the ELDERCARE-AF results (p=0.023), control arm different than VKA (p=0.006) and the prevalence of hypertension (p=0.042) were outlined as main sources of heterogeneicity for stroke risk reduction. The type of DOAC was the main source of source of heterogeneicity for all-cause mortality (p&lt;0.001) and major bleeding (p=0.03) risk reduction. No small-study effect was found for any endpoint except for intracranial bleeding (Harbor test p=0.029). Conclusions Treatment with DOACs in octogenarians reduces the incidence of stroke, all-cause mortality and intracranial bleeding as compared to VKA. Funding Acknowledgement Type of funding sources: None." @default.
• W4386660211 created "2023-09-13" @default.
• W4386660211 creator A5004444515 @default.
• W4386660211 creator A5038069972 @default.
• W4386660211 creator A5039483633 @default.
• W4386660211 creator A5043743986 @default.
• W4386660211 creator A5047250588 @default.
• W4386660211 creator A5070470399 @default.
• W4386660211 creator A5071519757 @default.
• W4386660211 creator A5077408960 @default.
• W4386660211 creator A5083372453 @default.
• W4386660211 creator A5084282364 @default.
• W4386660211 date "2021-10-01" @default.
• W4386660211 modified "2023-09-27" @default.
• W4386660211 title "Clinical benefit of direct oral anticoagulants vs. vitamin-K antagonist in octogenarians with atrial fibrillation" @default.
• W4386660211 doi "https://doi.org/10.1093/eurheartj/ehab724.2827" @default.
• W4386660211 hasPublicationYear "2021" @default.
• W4386660211 type Work @default.
• W4386660211 citedByCount "0" @default.
• W4386660211 crossrefType "journal-article" @default.
• W4386660211 hasAuthorship W4386660211A5004444515 @default.
• W4386660211 hasAuthorship W4386660211A5038069972 @default.
• W4386660211 hasAuthorship W4386660211A5039483633 @default.
• W4386660211 hasAuthorship W4386660211A5043743986 @default.
• W4386660211 hasAuthorship W4386660211A5047250588 @default.
• W4386660211 hasAuthorship W4386660211A5070470399 @default.
• W4386660211 hasAuthorship W4386660211A5071519757 @default.
• W4386660211 hasAuthorship W4386660211A5077408960 @default.
• W4386660211 hasAuthorship W4386660211A5083372453 @default.
• W4386660211 hasAuthorship W4386660211A5084282364 @default.
• W4386660211 hasBestOaLocation W43866602111 @default.
• W4386660211 hasConcept C126322002 @default.
• W4386660211 hasConcept C127413603 @default.
• W4386660211 hasConcept C164705383 @default.
• W4386660211 hasConcept C2776301958 @default.
• W4386660211 hasConcept C2776704044 @default.
• W4386660211 hasConcept C2778661090 @default.
• W4386660211 hasConcept C2778810321 @default.
• W4386660211 hasConcept C2779161974 @default.
• W4386660211 hasConcept C2780290652 @default.
• W4386660211 hasConcept C2780638905 @default.
• W4386660211 hasConcept C2780645631 @default.
• W4386660211 hasConcept C71924100 @default.
• W4386660211 hasConcept C78519656 @default.
• W4386660211 hasConcept C90924648 @default.
• W4386660211 hasConceptScore W4386660211C126322002 @default.
• W4386660211 hasConceptScore W4386660211C127413603 @default.
• W4386660211 hasConceptScore W4386660211C164705383 @default.
• W4386660211 hasConceptScore W4386660211C2776301958 @default.
• W4386660211 hasConceptScore W4386660211C2776704044 @default.
• W4386660211 hasConceptScore W4386660211C2778661090 @default.
• W4386660211 hasConceptScore W4386660211C2778810321 @default.
• W4386660211 hasConceptScore W4386660211C2779161974 @default.
• W4386660211 hasConceptScore W4386660211C2780290652 @default.
• W4386660211 hasConceptScore W4386660211C2780638905 @default.
• W4386660211 hasConceptScore W4386660211C2780645631 @default.
• W4386660211 hasConceptScore W4386660211C71924100 @default.
• W4386660211 hasConceptScore W4386660211C78519656 @default.
• W4386660211 hasConceptScore W4386660211C90924648 @default.
• W4386660211 hasIssue "Supplement_1" @default.
• W4386660211 hasLocation W43866602111 @default.
• W4386660211 hasOpenAccess W4386660211 @default.
• W4386660211 hasPrimaryLocation W43866602111 @default.
• W4386660211 hasRelatedWork W1956559559 @default.
• W4386660211 hasRelatedWork W2765903299 @default.
• W4386660211 hasRelatedWork W2778270325 @default.
• W4386660211 hasRelatedWork W2907026589 @default.
• W4386660211 hasRelatedWork W3026325529 @default.
• W4386660211 hasRelatedWork W3038461906 @default.
• W4386660211 hasRelatedWork W3173880122 @default.
• W4386660211 hasRelatedWork W3199441999 @default.
• W4386660211 hasRelatedWork W4220911984 @default.
• W4386660211 hasRelatedWork W4319019627 @default.
• W4386660211 hasVolume "42" @default.
• W4386660211 isParatext "false" @default.
• W4386660211 isRetracted "false" @default.
• W4386660211 workType "article" @default.